Selective blockade of tumor angiogenesis

Cell Cycle

Volumn 11, Issue 12, 2012, Pages 2253-2259

  Chaudhary, Amit ^a   St Croix, Brad ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Amino acids; Antibodies; ANTXR1; Autophagy; Endothelial; Growth factors; TEM8

Indexed keywords

ANTI TUMOR ENDOTHELIAL MARKER 8 ANTIBODY; ANTIBODY; CELL SURFACE RECEPTOR; IRINOTECAN; TUMOR ENDOTHELIAL MARKER 8 PROTEIN; UNCLASSIFIED DRUG;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; CANCER GROWTH; CANCER INHIBITION; HUMAN; MELANOMA; NONHUMAN; PROTEIN FUNCTION; REVIEW; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT;

MUS;

EID: 84862848798     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.20374     Document Type: Review

References (57)

1. Taraboletti G, Rusnati M, Ragona L, Colombo G. Targeting tumor angiogenesis with TSP-1-based compounds: rational design of antiangiogenic mimetics of endogenous inhibitors. Oncotarget 2010; 1:662-73; PMID:21317461.
2. Kaur S, Roberts DD. CD47 applies the brakes to angiogenesis via vascular endothelial growth factor receptor-2. Cell Cycle 2011; 10:10-2; PMID:21191182; http://dx.doi.org/10.4161/cc.10.1.14324.
3. Shichiri M, Tanaka Y. Inhibition of cancer progression by rifampicin: involvement of antiangiogenic and antitumor effects. Cell Cycle 2010; 9:64-8; PMID:20016271; http://dx.doi.org/10.4161/cc.9.1.10354.
4. Acevedo VD, Ittmann M, Spencer DM. Paths of FGFR-driven tumorigenesis. Cell Cycle 2009; 8:580- 8; PMID:19182515; http://dx.doi.org/10.4161/ cc.8.4.7657.
5. Kerbel RS. Tumor angiogenesis. N Engl J Med 2008; 358:2039-49; PMID:18463380; http://dx.doi.org/10.1056/NEJMra0706596.
6. Samant RS, Shevde LA. Recent advances in antiangiogenic therapy of cancer. Oncotarget 2011; 2:122-34; PMID:21399234.
7. Ebos JM, Kerbel RS. Antiangiogenic therapy: impact on invasion, disease progression and metastasis. Nat Rev Clin Oncol 2011; 8:210-21; PMID:21364524;http://dx.doi.org/10.1038/nrclinonc.2011.21.
8. Chen HX, Cleck JN. Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol 2009; 6:465-77; PMID:19581909; http://dx.doi.org/10.1038/nrclinonc.2009.94.
9. Verheul HM, Pinedo HM. Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer 2007; 7:475-85; PMID:17522716; http://dx.doi.org/10.1038/nrc2152.
10. Eremina V, Cui S, Gerber H, Ferrara N, Haigh J, Nagy A, et al. Vascular endothelial growth factor a signaling in the podocyte-endothelial compartment is required for mesangial cell migration and survival. J Am Soc Nephrol 2006; 17:724- 35; PMID:16436493; http://dx.doi.org/10.1681/ASN.2005080810.
11. Sung HK, Michael IP, Nagy A. Multifaceted role of vascular endothelial growth factor signaling in adult tissue physiology: an emerging concept with clinical implications. Curr Opin Hematol 2010; 17:206-12; PMID:20216210.
12. Lee S, Chen TT, Barber CL, Jordan MC, Murdock J, Desai S, et al. Autocrine VEGF signaling is required for vascular homeostasis. Cell 2007; 130:691-703; PMID:17719546; http://dx.doi.org/10.1016/j.cell.2007.06.054.
13. Rouhi P, Lee SL, Cao Z, Hedlund EM, Jensen LD, Cao Y. Pathological angiogenesis facilitates tumor cell dissemination and metastasis. Cell Cycle 2010; 9:913-7; PMID:20160500; http://dx.doi.org/10.4161/cc.9.5.10853.
14. St. Croix B, Rago C, Velculescu V, Traverso G, Romans KE, Montgomery E, et al. Genes expressed in human tumor endothelium. Science 2000; 289:1197-202; PMID:10947988; http://dx.doi.org/10.1126/science.289.5482.1197.
15. Nanda A, Carson-Walter EB, Seaman S, Barber TD, Stampfl J, Singh S, et al. TEM8 interacts with the cleaved C5 domain of collagen alpha 3(VI). Cancer Res 2004; 64:817-20; PMID:14871805; http://dx.doi.org/10.1158/0008-5472.CAN-03- 2408.
16. Seaman S, Stevens J, Yang MY, Logsdon D, Graff- Cherry C, St. Croix B. Genes that distinguish physiological and pathological angiogenesis. Cancer Cell 2007; 11:539-54; PMID:17560335; http://dx.doi.org/10.1016/j.ccr.2007.04.017.
17. Oh P, Li Y, Yu J, Durr E, Krasinska KM, Carver LA, et al. Subtractive proteomic mapping of the endothelial surface in lung and solid tumours for tissue-specific therapy. Nature 2004; 429:629- 35; PMID:15190345; http://dx.doi.org/10.1038/nature02580.
18. Beaty RM, Edwards JB, Boon K, Siu IM, Conway JE, Riggins GJ. PLXDC1 (TEM7) is identified in a genome-wide expression screen of glioblastoma endothelium. J Neurooncol 2007; 81:241-8; PMID:17031559; http://dx.doi.org/10. 1007/s11060-006-9227-9.
19. Parker BS, Argani P, Cook BP, Liangfeng H, Chartrand SD, Zhang M, et al. Alterations in vascular gene expression in invasive breast carcinoma. Cancer Res 2004; 64:7857-66; PMID:15520192; http://dx.doi.org/10.1158/0008-5472.CAN-04- 1976.
20. Carson-Walter E, St. Croix B. Molecular Targets of Tumor Vasculature. In: Aird WC, Ed. Endothelial Cell Phenotypes in Health and Disease: Marcel Dekker, Inc. 2005.
21. Madden SL, Cook BP, Nacht M, Weber WD, Callahan MR, Jiang Y, et al. Vascular gene expression in nonneoplastic and malignant brain. Am J Pathol 2004; 165:601-8; PMID:15277233; http://dx.doi.org/10.1016/S0002-9440(10)63324-X.
22. Roesli C, Neri D. Methods for the identification of vascular markers in health and disease: from the bench to the clinic. J Proteomics 2010; 73:2219- 29; PMID:20541635; http://dx.doi.org/10.1016/j.jprot.2010.05.017.
23. Neri D, Bicknell R. Tumour vascular targeting. Nat Rev Cancer 2005; 5:436-46; PMID:15928674; http://dx.doi.org/10.1038/nrc1627.
24. Hajitou A, Pasqualini R, Arap W. Vascular targeting: recent advances and therapeutic perspectives. Trends Cardiovasc Med 2006; 16:80-8; PMID:16546688; http://dx.doi.org/10.1016/j.tcm.2006.01.003.
25. Bradley KA, Mogridge J, Mourez M, Collier RJ, Young JA. Identification of the cellular receptor for anthrax toxin. Nature 2001; 414:225-9; PMID:11700562; http://dx.doi.org/10.1038/n35101999.
26. Scobie HM, Rainey GJ, Bradley KA, Young JA. Human capillary morphogenesis protein 2 functions as an anthrax toxin receptor. Proc Natl Acad Sci USA 2003; 100:5170-4; PMID:12700348; http://dx.doi.org/10.1073/pnas.0431098100.
27. Liu S, Crown D, Miller-Randolph S, Moayeri M, Wang H, Hu H, et al. Capillary morphogenesis protein-2 is the major receptor mediating lethality of anthrax toxin in vivo. Proc Natl Acad Sci USA 2009; 106:12424-9; PMID:19617532; http://dx.doi.org/10.1073/pnas.0905409106.
28. Liu S, Miller-Randolph S, Crown D, Moayeri M, Sastalla I, Okugawa S, et al. Anthrax toxin targeting of myeloid cells through the CMG2 receptor is essential for establishment of Bacillus anthracis infections in mice. Cell Host Microbe 2010; 8:455- 62; PMID:21075356; http://dx.doi.org/10.1016/j.chom.2010. 10.004.
29. Chen KH, Liu S, Bankston LA, Liddington RC, Leppla SH. Selection of anthrax toxin protective antigen variants that discriminate between the cellular receptors TEM8 and CMG2 and achieve targeting of tumor cells. J Biol Chem 2007; 282:9834-45; PMID:17251181; http://dx.doi.org/10.1074/jbc.M611142200.
30. Hotchkiss KA, Basile CM, Spring SC, Bonuccelli G, Lisanti MP, Terman BI. TEM8 expression stimulates endothelial cell adhesion and migration by regulating cell-matrix interactions on collagen. Exp Cell Res 2005; 305:133-44; PMID:15777794; http://dx.doi.org/10.1016/j.yexcr.2004.12.025.
31. Bell SE, Mavila A, Salazar R, Bayless KJ, Kanagala S, Maxwell SA, et al. Differential gene expression during capillary morphogenesis in 3D collagen matrices: regulated expression of genes involved in basement membrane matrix assembly, cell cycle progression, cellular differentiation and G-protein signaling. J Cell Sci 2001; 114:2755-73; PMID:11683410.
32. Dowling O, Difeo A, Ramirez MC, Tukel T, Narla G, Bonafe L, et al. Mutations in capillary morphogenesis gene-2 result in the allelic disorders juvenile hyaline fibromatosis and infantile systemic hyalinosis. Am J Hum Genet 2003; 73:957-66; PMID:12973667; http://dx.doi.org/10.1086/378781.
33. Hanks S, Adams S, Douglas J, Arbour L, Atherton DJ, Balci S, et al. Mutations in the gene encoding capillary morphogenesis protein 2 cause juvenile hyaline fibromatosis and infantile systemic hyalinosis. Am J Hum Genet 2003; 73:791-800; PMID:14508707; http://dx.doi.org/10.1086/378418.
34. Deuquet J, Lausch E, Superti-Furga A, van der Goot FG. The dark sides of capillary morphogenesis gene 2. EMBO J 2012; 31:3-13; PMID:22215446; http://dx.doi.org/10.1038/emboj.2011.442.
35. Tanaka K, Ebihara T, Kusubata M, Adachi E, Arai M, Kawaguchi N, et al. Abnormal collagen deposition in fibromas from patient with juvenile hyaline fibromatosis. J Dermatol Sci 2009; 55:197- 200; PMID:19592224; http://dx.doi.org/10.1016/j.jdermsci.2009.06.005.
36. Murata K, Motoyama T, Suka M, Ohno M, Kuboki Y. High production of type VI collagen in multiple fibromatosis with multiple articular dysplasia. Biochem Biophys Res Commun 1987; 147:275-81; PMID:3632670; http://dx.doi.org/10.1016/ S0006-291X(87)80117-1.
37. Glover MT, Lake BD, Atherton DJ. Infantile systemic hyalinosis: newly recognized disorder of collagen? Pediatrics 1991; 87:228-34; PMID:1702887.
38. Katagiri K, Takasaki S, Fujiwara S, Kayashima K, Ono T, Shinkai H. Purification and structural analysis of extracellular matrix of a skin tumor from a patient with juvenile hyaline fibromatosis. J Dermatol Sci 1996; 13:37-48; PMID:8902652; http://dx.doi.org/10.1016/0923-1811(95)00492-0.
39. Iwata S, Horiuchi R, Maeda H, Ishikawa H. Systemic hyalinosis or juvenile hyaline fibromatosis. Ultrastructural and biochemical study of cultured skin fibroblasts. Arch Dermatol Res 1980; 267:115- 21; PMID:6157366; http://dx.doi.org/10.1007/BF00569097.
40. Tzellos TG, Dionyssopoulos A, Klagas I, Karakiulakis G, Lazaridis L, Papakonstantinou E. Differential glycosaminoglycan expression and hyaluronan homeostasis in juvenile hyaline fibromatosis. J Am Acad Dermatol 2009; 61:629-38; PMID:19559501; http://dx.doi.org/10.1016/j.jaad.2009.03.042.
41. Stucki U, Spycher MA, Eich G, Rossi A, Sacher P, Steinmann B, et al. Infantile systemic hyalinosis in siblings: clinical report, biochemical and ultrastructural findings, and review of the literature. Am J Med Genet 2001; 100:122-9; PMID:11298373; http://dx.doi.org/10.1002/1096-8628(20010422)100: 2<122::AID-AJMG1236>3.0.CO;2-0.
42. Cullen M, Seaman S, Chaudhary A, Yang MY, Hilton MB, Logsdon D, et al. Host-derived tumor endothelial marker 8 promotes the growth of melanoma. Cancer Res 2009; 69:6021-6; PMID:19622764; http://dx.doi.org/10.1158/0008-5472.CAN-09- 1086.
43. Chaudhary A, Hilton MB, Seaman S, Haines DC, Stevenson S, Lemotte PK, et al. TEM8/ANTXR1 blockade inhibits pathological angiogenesis and potentiates tumoricidal responses against multiple cancer types. Cancer Cell 2012; 21:212-26; PMID:22340594; http://dx.doi.org/10.1016/j.ccr.2012.01.004.
44. Chaudhary A, St. Croix B. Unpublished Observations.
45. Yang MY, Chaudhary A, Seaman S, Dunty J, Stevens J, Elzarrad MK, et al. The cell surface structure of tumor endothelial marker 8 (TEM8) is regulated by the actin cytoskeleton. Biochim Biophys Acta 2011; 1813:39-49; PMID:21129411; http://dx.doi.org/10.1016/j.bbamcr.2010.11.013.
46. Bonuccelli G, Sotgia F, Frank PG, Williams TM, de Almeida CJ, Tanowitz HB, et al. ATR/TEM8 is highly expressed in epithelial cells lining Bacillus anthracis' three sites of entry: implications for the pathogenesis of anthrax infection. Am J Physiol Cell Physiol 2005; 288:1402-10; PMID:15689409;http://dx. doi.org/10.1152/ajpcell.00582.2004.
47. Eberhard A, Kahlert S, Goede V, Hemmerlein B, Plate KH, Augustin HG. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res 2000; 60:1388-93; PMID:10728704.
48. Dallas NA, Fan F, Gray MJ, Van Buren G, 2nd, Lim SJ, Xia L, et al. Functional significance of vascular endothelial growth factor receptors on gastrointestinal cancer cells. Cancer Metastasis Rev 2007; 26:433-41; PMID:17786539; http://dx.doi.org/10.1007/s10555-007-9070-2.
49. Masood R, Cai J, Zheng T, Smith DL, Hinton DR, Gill PS. Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptorpositive human tumors. Blood 2001; 98:1904-13; PMID:11535528; http://dx.doi.org/10.1182/blood.V98.6.1904.
50. Liu B, Earl HM, Baban D, Shoaibi M, Fabra A, Kerr DJ, et al. Melanoma cell lines express VEGF receptor KDR and respond to exogenously added VEGF. Biochem Biophys Res Commun 1995; 217:721- 7; PMID:8554590; http://dx.doi.org/10. 1006/bbrc.1995.2832.
51. Slongo ML, Molena B, Brunati AM, Frasson M, Gardiman M, Carli M, et al. Functional VEGF and VEGF receptors are expressed in human medulloblastomas. Neuro Oncol 2007; 9:384-92; PMID:17704359; http://dx.doi.org/10.1215/15228517- 2007-032.
52. Fuchs BC, Bode BP. Amino acid transporters ASCT2 and LAT1 in cancer: partners in crime? Semin Cancer Biol 2005; 15:254-66; PMID:15916903; http://dx.doi.org/10.1016/j.semcancer.2005.04.005.
53. Yamaguchi T, Bando H, Mori T, Takahashi K, Matsumoto H, Yasutome M, et al. Overexpression of soluble vascular endothelial growth factor receptor 1 in colorectal cancer: Association with progression and prognosis. Cancer Sci 2007; 98:405-10; PMID:17214745; http://dx.doi.org/10.1111/j.1349-7006.2007.00402.x.
54. Lamszus K, Ulbricht U, Matschke J, Brockmann MA, Fillbrandt R, Westphal M. Levels of soluble vascular endothelial growth factor (VEGF) receptor 1 in astrocytic tumors and its relation to malignancy, vascularity and VEGF-A. Clin Cancer Res 2003; 9:1399-405; PMID:12684411.
55. Gerber HP, Condorelli F, Park J, Ferrara N. Differential transcriptional regulation of the two vascular endothelial growth factor receptor genes. Flt-1, but not Flk-1/KDR, is upregulated by hypoxia. J Biol Chem 1997; 272:23659-67; PMID:9295307; http://dx.doi.org/10.1074/jbc.272.38.23659.
56. Kroemer G, Mariño G, Levine B. Autophagy and the integrated stress response. Mol Cell 2010; 40:280- 93; PMID:20965422; http://dx.doi.org/10.1016/j. molcel.2010.09.023.
57. Lum JJ, Bauer DE, Kong M, Harris MH, Li C, Lindsten T, et al. Growth factor regulation of autophagy and cell survival in the absence of apoptosis. Cell 2005; 120:237-48; PMID:15680329; http://dx.doi.org/10.1016/j.cell.2004.11. 046.